NCT03558165

Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Assay

Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Cancer Panel

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 134 (actual)
• Sponsor: University Health Network, Toronto · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Currently, publicly funded standard of care testing in Ontario for stage IV lung cancer patients uses individual gene tests to look for mutations in the EGFR and ALK genes. This testing broadens treatment options for patients, however there are other gene mutations with corresponding targeted treatments that are not routinely tested for. This study will evaluate the utility and added value of using a next generation sequencing (NGS) panel, the Oncomine Comprehensive Assay v3, to profile stage IV lung cancer patients.

Conditions

• Lung Cancer Stage IV

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Oncomine Comprehensive Assay	Stage IV lung adenocarcinoma patients will have previously biopsied tumor tissue tested with the Oncomine Comprehensive Assay

Timeline

• Start date: 2018-03-01
• Primary completion: 2020-08-20
• Completion: 2022-02-18
• First posted: 2018-06-15
• Last updated: 2022-05-17

Locations

1 site across 1 country: Canada